Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 2:58 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 625–648 of 1,280 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Infection Prophylaxis Clear all

Conditions: Shingles, Herpes Zoster, Postherpetic Neuralgia
Interventions: FV-100, valacyclovir; Drug
Lead sponsor: ContraVir Pharmaceuticals, Inc.; Industry
Eligibility: 30 Years and older
Enrollment: 237 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Webster, Texas

Conditions: Heart Failure, Healthcare Associated Infection, Ventricular Assist Device
Interventions: VAD Infection Prevention Survey; Other
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 208 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: HIV Prevention, Sexually Transmitted Diseases, Pre-Exposure Prophylaxis
Interventions: HOME Study intervention, Control; Behavioral
Lead sponsor: Public Health Foundation Enterprises, Inc.; Other
Eligibility: 18 Years to 35 Years · Male only
Enrollment: 104 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: San Francisco, California

Conditions: HPV Infection, Vaccine-Preventable Diseases
Interventions: HPV game; Behavioral
Lead sponsor: Michigan State University; Other
Eligibility: 11 Years to 14 Years
Enrollment: 133 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: East Lansing, Michigan

Conditions: Complicated Appendicitis, Acute Appendicitis
Interventions: Ceftriaxone, Intra-peritoneal Fluid Aspiration; Drug · Procedure
Lead sponsor: Johns Hopkins All Children's Hospital; Other
Eligibility: 3 Years to 18 Years
Enrollment: 190 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: St. Petersburg, Florida

Conditions: Hiv, Adolescent Behavior, Sex, Safe
Interventions: Queer Sex Ed, Keep It Up, Keep It Up-Control, Young Men's Health Project; Behavioral
Lead sponsor: Northwestern University; Other
Eligibility: 13 Years to 18 Years · Male only
Enrollment: 1,306 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Mycobacterium Avium-intracellulare Infection, HIV Infections
Interventions: Rifabutin; Drug
Lead sponsor: Pharmacia; Industry
Eligibility: 18 Years and older
Enrollment: 750 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 31
States / cities: Phoenix, Arizona • Berkeley, California • Beverly Hills, California + 22 more

Conditions: Influenza A Virus, H5N1 Subtype
Interventions: VRC-AVIDNA036-00-VP, Monovalent Influenza Subunit Virion (Inactive H5N1) Vaccine; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Healthy Subject, Human Papillomavirus Infection
Interventions: carrageenan-containing gel, Placebo, Laboratory Biomarker Analysis, Questionnaire Administration; Drug · Other
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 19 Years to 35 Years · Female only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Newark, New Jersey

Conditions: CIED Related Infection
Interventions: TYRX™ Absorbable Antibacterial Envelope; Device
Lead sponsor: Medtronic Cardiac Rhythm and Heart Failure; Industry
Eligibility: 18 Years and older
Enrollment: 7,075 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2018
U.S. locations: 120
States / cities: Anchorage, Alaska • Mesa, Arizona • Scottsdale, Arizona + 94 more

Conditions: COVID-19, SAR
Interventions: CBDRA60 supplement, Placebo; Dietary Supplement
Lead sponsor: Anewsha Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Hanover, Michigan

Conditions: Urinary Tract Infections, Recurrent
Interventions: Trimethoprim, Methenamine hippurate; Drug
Lead sponsor: Endeavor Health; Other
Eligibility: 18 Years to 99 Years · Female only
Enrollment: 92 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Skokie, Illinois

Conditions: Liver Transplant Infection, Fungal Infection
Interventions: Rezafungin, Standard of care antifungal prophylaxis; Drug
Lead sponsor: Fernanda P Silveira, MD, MS; Other
Eligibility: 18 Years and older
Enrollment: 385 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Coronavirus Disease 2019 (COVID-19)
Interventions: Garadacimab, Factor XIIa Antagonist Monoclonal Antibody, Placebo; Biological · Drug
Lead sponsor: CSL Behring; Industry
Eligibility: 18 Years and older
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 14
States / cities: Bradenton, Florida • St. Petersburg, Florida • Mason City, Iowa + 11 more

Conditions: Antibiotic-associated Diarrhea, Clostridium Difficile
Interventions: Lactobacillus reuteri; Dietary Supplement
Lead sponsor: Case Western Reserve University; Other
Eligibility: 18 Years and older
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2017
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Influenza, Healthy
Interventions: Bivalent influenza vaccine, Placebo; Biological · Other
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 2
States / cities: Stockbridge, Georgia • Portland, Oregon

Conditions: HIV Infections, Sexual Risk Behavior, Substance Use Risks
Interventions: Positive Choice; Behavioral
Lead sponsor: National Institute on Drug Abuse (NIDA); NIH
Eligibility: 18 Years and older
Enrollment: 497 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2006
U.S. locations: 5
States / cities: Oakland, California • San Francisco, California • San Leandro, California

Conditions: COVID-19, Corona Virus Infection, ARDS, Acute Respiratory Distress Syndrome
Interventions: Hydroxychloroquine, Placebo; Drug · Other
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 1,483 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 2
States / cities: Minneapolis, Minnesota

Conditions: COVID-19, Venous Thromboembolism, Arterial Thrombosis
Interventions: Unfractionated Heparin IV, Enoxaparin 1 mg/kg, Clopidogrel, Unfractionated heparin SC, Enoxaparin 40 mg SC; Drug
Lead sponsor: The TIMI Study Group; Other
Eligibility: 18 Years and older
Enrollment: 390 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: SARS-CoV-2 Infection
Interventions: 25 µg SpFN_1B-06-PL + ALFQ (QS21 Adjuvant), Sodium chloride, USP, for injection (0.9% NaCl), 50 µg SpFN_1B-06-PL + ALFQ (QS21 Adjuvant); Biological · Drug
Lead sponsor: U.S. Army Medical Research and Development Command; Federal
Eligibility: 18 Years to 55 Years
Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Silver Spring, Maryland

Conditions: Coronavirus Disease (COVID-19)
Interventions: Molnupiravir, Placebo; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 2,441 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 59
States / cities: Birmingham, Alabama • Mesa, Arizona • Tucson, Arizona + 53 more

Conditions: HIV Infections
Interventions: HIV risk education; Behavioral
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 64 Years
Enrollment: 570 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: COVID-19
Interventions: HB-adMSCs; Biological
Lead sponsor: Hope Biosciences Research Foundation; Industry
Eligibility: Not listed
Enrollment: 51 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Sugar Land, Texas

Conditions: Covid19
Interventions: VXA-CoV2-1; Biological
Lead sponsor: Vaxart; Industry
Eligibility: 18 Years to 54 Years
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Cypress, California

Search by objective public record fields.

A Comparative Study of FV-100 vs. Valacyclovir for the Prevention of Post-Herpetic Neuralgia

Ventricular Assist Device (VAD) Infection Prevention Survey

HOME Study: a Combination Support Package to Increase Uptake of PrEP and HIV/STI Testing

Game-Based Intervention to Promote HPV Vaccination

Antibiotic Instillation in Appendicitis

A Pragmatic Trial of An Adaptive eHealth HIV Prevention Program for Diverse Adolescent MSM

Rifabutin Therapy for the Prevention of Mycobacterium Avium Complex (MAC) Bacteremia in AIDS Patients With CD4 Counts = or < 200: A Double-Blind, Placebo-Controlled Trial

An Open-Label, Randomized Phase I Study in Healthy Adults of the Safety and Immunogenicity of Prime-Boost Intervals With Monovalent Influenza Subunit Virion (H5N1) Vaccine, A/Indonesia/05/2005 (Sanofi Pasteur, Inc.) Administered Alone or Following Re...

Carrageenan-Containing Gel in Reducing the Rate of HPV Infection in Healthy Participants

World-wide Randomized Antibiotic Envelope Infection Prevention Trial

(CBDRA60) to Prevent or Reduce Symptoms of COVID-19 and Prevention of Post-Acute Sequelae of SARS-CoV-2 Infection PASC

Methenamine Hippurate Versus Trimethoprim in the Prevention of Recurrent UTIs

Rezafungin Prophylaxis in Liver Transplant

Treatment With CSL312 in Adults With Coronavirus Disease 2019 (COVID-19)

Lactobacillus Reuteri in the Prevention of Antibiotic Associated-diarrhea and Clostridium Difficile

D2560C00015 FluMist Annual Safety Study 2018

Positive Choice: Prevention for Positive Health

Pre-exposure Prophylaxis for SARS-Coronavirus-2

Prevention of Arteriovenous Thrombotic Events in Critically-Ill COVID-19 Patients Trial

PHASE 1 SARS-COV-2-Spike-Ferritin-Nanoparticle (SpFN) Vaccine With ALFQ Adjuvant for Prevention of COVID-19

Study of MK-4482 for Prevention of Coronavirus Disease 2019 (COVID-19) in Adults (MK-4482-013)

Rapid HIV Testing for Emergency Department Patients

A Clinical Trial to Determine the Safety and Efficacy of HB-adMSCs to Provide Protection Against COVID-19

Safety and Immunogenicity Trial of an Oral SARS-CoV-2 Vaccine (VXA-CoV2-1) for Prevention of COVID-19 in Healthy Adults and Boost (VXA-CoV2-1.1-S) at 1 Year Post Initial Vaccination in Subset of Subjects